Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

Published:2010-02 Issue:1 Volume:36 Page:69-74
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Mauri Davide,Kamposioras Konstantinos,Tsali Lamprini,Bristianou Magdalini,Valachis Antonis,Karathanasi Ioanna,Georgiou Christos,Polyzos Nikolaos P.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference26 articles.

1. Multiple treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer;Mauri;J Natl Cancer Inst,2008

2. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer;Esteva;J Clin Oncol,2002

3. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer;Hainsworth;J Clin Oncol,1998

4. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis;Tomiak;J Clin Oncol,1994

5. Docetaxel administered on a weekly basis for metastatic breast cancer;Burstein;J Clin Oncol,2000

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The landscape of use of NCCN-guideline chemotherapy regimens in stage I-IIIA breast cancer in an integrated healthcare delivery system;Breast Cancer Research and Treatment;2024-08-16

2. Mexican breast cancer consensus. Management of advanced breast cancer;Gaceta Mexicana de Oncolog�a;2024-06-25

3. Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review;Breast Cancer: Targets and Therapy;2024-04

4. Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy;Medical Oncology;2023-12-16

5. Sequencing systemic therapy in hormone-receptor positive metastatic breast cancer: a modern paradigm;Chinese Clinical Oncology;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3